Poor outcomes associated with neutropenia after kidney transplantation: Analysis of united states renal data system

Transplantation

Volumn 92, Issue 1, 2011, Pages 36-40

  Hurst, Frank P ^a   Belur, Pallavi ^a   Nee, Robert ^a   Agodoa, Lawrence Y ^b   Patel, Purav ^c   Abbott, Kevin C ^a   Jindal, Rahul M ^a,d  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^d GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Granulocyte colony stimulating factors; Neutropenia after kidney transplantation; United States Renal Data System

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; GRANULOCYTE COLONY STIMULATING FACTOR; HLA ANTIGEN; INTERLEUKIN 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PANEL REACTIVE ANTIBODY; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CADAVER DONOR; CAUCASIAN; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DELAYED GRAFT FUNCTION; DONOR SELECTION; ETHNIC DIFFERENCE; FEMALE; GRAFT FAILURE; GRAFT SURVIVAL; HLA MATCHING; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY; NEUTROPENIA; POSTTRANSPLANT NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK REDUCTION; SEX DIFFERENCE; TREATMENT OUTCOME; UNITED STATES;

ADULT; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HUMANS; IMMUNOSUPPRESSION; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; LEUKOPENIA; MALE; MEDICARE; MIDDLE AGED; NEUTROPENIA; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 79959640011     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31821c1e70     Document Type: Article

References (24)

1. Ojo AO, Hanson JA, Wolfe RA, et al. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57: 307.
2. Zafrani L, Truffaut L, Kreis H, et al. Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: A retrospective study. Am J Transplant 2009; 9: 1816.
3. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transpl 2009; 9: S1.
4. Heaf J. Bone marrow function during quadruple immunosuppressive therapy after renal transplantation. Clin Nephrol 1993; 40: 332.
5. EBPG Expert Group on Renal Transplantation. European best practice guideline for renal transplantation. Section IV: Long-term management of the transplant patient. IV. 9.2. Haematological complications. Leucopenia. Nephrol Dial Transplant 2002; 17(suppl 4): 49.
6. Brennan DC, Flavin K, Lowell JA, et al. Leukocyte response to thymoglobulin or atgam for induction immunosuppression in a randomized, double-blind clinical trial in renal transplant patients. Transplant Proc 1999; 31(suppl 3B): 16S.
7. Brennan DC, Daller JA, Lake KD, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355: 1967.
8. Oesterwitz H, Horpacsy G, May G, et al. Frequency of leucopenia incidents following azathioprine therapy after kidney transplantation. European Urol 1978; 4: 167.
9. Pollak R, Nishikawa RA, Mozes MF, et al. Azathioprine-induced leukopenia-Clinical significance in renal transplantation. J Surg Res 1980; 29: 258.
10. Moreso F, Serón D, Morales JM, et al. Incidence of leucopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses. Clin Transplant 1998; 12: 198.
11. Hong JC, Barry D. Sirolimus-induced thrombocytopenia and leucopenia in renal transplant recipients: Risk factors, incidence, progression, and management. Clin Transplant 2000; 69: 2085.
12. Royer B, Zanetta G, Bérard M, et al. A neutropenia suggesting an interaction between valacyclovir and mycophenolate mofetil. Clin Transplant 2003; 17: 158.
13. Taber DJ, Ashcraft E, Baillie GM, et al. Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease. Transpl Infec Dis 2004; 6: 101.
14. Bradley PP, Warden GD, Maxwell JG, et al. Neutropenia and thrombocytopenia in renal allograft recipients treated with trimethoprimsulfamethoxazole. Ann Intern Med 1980; 93: 560.
15. Pelletier RP, Akin B, Henry ML, et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003; 17: 200.
16. Matsui K, Shibagaki Y, Sasaki H, et al. Mycophenolate mofetil-induced agranulocytosis in a renal transplant recipient. Clin Exp Nephrol 2010; 14: 637.
17. Peddi VR, Hariharan S, Schroeder TJ, et al. Role of granulocyte colony stimulating factor (G-CSF) in reversing neutropenia in renal allograft recipients. Clin Transplant 1996; 10: 20.
18. Rerolle JP, Szelag JC, Meur YL. Unexpected rate of severe leukopenia with the association of mycophenolate mofetil and valganciclovir in kidney transplant recipients. Nephrol Dial Transplant 2007; 22: 671.
19. Brum S, Nolasco F, Sousa J, et al. Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil. Transpl Proc 2008; 40: 752.
20. Hartmann EL, Gatesman M, Roskopf-Somerville J, et al. Management of leukopenia in kidney and pancreas transplant recipients. Clin Transplant 2008; 22: 822.
21. Turgeon N, Hovingh GK, Fishman JA, et al. Safety and efficacy of granulocyte colony-stimulating factor in kidney and liver transplant recipients. Tranplant Infect Dis 2000; 2: 15.
22. Abbott KC, Bucci JR, Cruess D, et al. Graft loss and acute coronary syndromes after renal transplantation in the United States. J Am Soc Nephrol 2002; 13: 2560.
23. Winkelmayer WC, Schneeweiss S, Mogun H, et al. Identification of individuals with CKD from Medicare claims data: A validation study. Am J Kidney Dis 2005; 46: 225.
24. Kern EF, Maney M, Miller DR, et al. Failure of ICD-9-CM codes to identify patients with comorbid chronic kidney disease in diabetes. Health Serv Res 2006; 41: 564.